TenNor Therapeutics amends Articles post-IPO, skips FY2025 dividend, reshuffles remuneration committee

Bulletin Express06-08

TenNor Therapeutics (Suzhou) Limited announced three board resolutions on 8 June 2026:

1. Articles of Association updated after H-share listing • The company finalised its Articles of Association to align with its Main Board debut on the Hong Kong Stock Exchange (HKEX) completed on 22 May 2026. • Key figures now formalised include the issuance of 8.86 million H-shares at a par value of RMB1.0 each, approved by HKEX on 21 May 2026. • Registered capital before the offering stood at RMB43.47 million, increasing total share capital to 52.33 million shares post-listing. • Editorial adjustments also clarify the scope of board authority and correct exchange references.

2. No final dividend for FY2025 • After reviewing the audited 2025 results, the board resolved not to declare a final dividend, citing provisions in the PRC Company Law and the company’s Articles.

3. Board committee change • Non-executive director Dr. Song Gaoguang joins the Remuneration and Appraisal Committee with immediate effect, restoring compliance with the committee-composition requirements stipulated in its working rules.

TenNor Therapeutics’ board comprises one executive director (Dr. Ma Zhenkun), one non-executive director (Dr. Song Gaoguang) and three independent non-executive directors (Mr. Lee Wai Kong, Albert; Dr. Ni Lin; and Dr. Li Leping).

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1198572504?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-08 22:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1198572504","market":"us","top_or_hot":-1,"title":"TenNor Therapeutics amends Articles post-IPO, skips FY2025 dividend, reshuffles remuneration committee","media":"Bulletin Express","content":"<p>TenNor Therapeutics (Suzhou) Limited announced three board resolutions on 8 June 2026:</p>\n<p>1. Articles of Association updated after H-share listing  \n• The company finalised its Articles of Association to align with its Main Board debut on the Hong Kong Stock Exchange (HKEX) completed on 22 May 2026.  \n• Key figures now formalised include the issuance of 8.86 million H-shares at a par value of RMB1.0 each, approved by HKEX on 21 May 2026.  \n• Registered capital before the offering stood at RMB43.47 million, increasing total share capital to 52.33 million shares post-listing.  \n• Editorial adjustments also clarify the scope of board authority and correct exchange references.</p>\n<p>2. No final dividend for FY2025  \n• After reviewing the audited 2025 results, the board resolved not to declare a final dividend, citing provisions in the PRC Company Law and the company’s Articles.</p>\n<p>3. Board committee change  \n• Non-executive director Dr. Song Gaoguang joins the Remuneration and Appraisal Committee with immediate effect, restoring compliance with the committee-composition requirements stipulated in its working rules.</p>\n<p>TenNor Therapeutics’ board comprises one executive director (Dr. Ma Zhenkun), one non-executive director (Dr. Song Gaoguang) and three independent non-executive directors (Mr. Lee Wai Kong, Albert; Dr. Ni Lin; and Dr. Li Leping).</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TenNor Therapeutics amends Articles post-IPO, skips FY2025 dividend, reshuffles remuneration committee</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTenNor Therapeutics amends Articles post-IPO, skips FY2025 dividend, reshuffles remuneration committee\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-08 22:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>TenNor Therapeutics (Suzhou) Limited announced three board resolutions on 8 June 2026:</p>\n<p>1. Articles of Association updated after H-share listing  \n• The company finalised its Articles of Association to align with its Main Board debut on the Hong Kong Stock Exchange (HKEX) completed on 22 May 2026.  \n• Key figures now formalised include the issuance of 8.86 million H-shares at a par value of RMB1.0 each, approved by HKEX on 21 May 2026.  \n• Registered capital before the offering stood at RMB43.47 million, increasing total share capital to 52.33 million shares post-listing.  \n• Editorial adjustments also clarify the scope of board authority and correct exchange references.</p>\n<p>2. No final dividend for FY2025  \n• After reviewing the audited 2025 results, the board resolved not to declare a final dividend, citing provisions in the PRC Company Law and the company’s Articles.</p>\n<p>3. Board committee change  \n• Non-executive director Dr. Song Gaoguang joins the Remuneration and Appraisal Committee with immediate effect, restoring compliance with the committee-composition requirements stipulated in its working rules.</p>\n<p>TenNor Therapeutics’ board comprises one executive director (Dr. Ma Zhenkun), one non-executive director (Dr. Song Gaoguang) and three independent non-executive directors (Mr. Lee Wai Kong, Albert; Dr. Ni Lin; and Dr. Li Leping).</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06872","symbol_name":"丹诺医药-B","start_time":0,"source_url":"","article_id":"1198572504","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1198572504","pubTimestamp":1780928586,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"TenNor Therapeutics (Suzhou) Limited announced three board resolutions on 8 June 2026: 1. Articles of Association updated after H-share listing   • The company finalised its Articles of Association...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06872":"丹诺医药-B"},"translate_title":"TenNor Therapeutics修改IPO后条款，跳过2025财年股息，改组薪酬委员会","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06872":1},"content_text":"TenNor Therapeutics (Suzhou) Limited announced three board resolutions on 8 June 2026:\n1. Articles of Association updated after H-share listing  \n• The company finalised its Articles of Association to align with its Main Board debut on the Hong Kong Stock Exchange (HKEX) completed on 22 May 2026.  \n• Key figures now formalised include the issuance of 8.86 million H-shares at a par value of RMB1.0 each, approved by HKEX on 21 May 2026.  \n• Registered capital before the offering stood at RMB43.47 million, increasing total share capital to 52.33 million shares post-listing.  \n• Editorial adjustments also clarify the scope of board authority and correct exchange references.\n2. No final dividend for FY2025  \n• After reviewing the audited 2025 results, the board resolved not to declare a final dividend, citing provisions in the PRC Company Law and the company’s Articles.\n3. Board committee change  \n• Non-executive director Dr. Song Gaoguang joins the Remuneration and Appraisal Committee with immediate effect, restoring compliance with the committee-composition requirements stipulated in its working rules.\nTenNor Therapeutics’ board comprises one executive director (Dr. Ma Zhenkun), one non-executive director (Dr. Song Gaoguang) and three independent non-executive directors (Mr. Lee Wai Kong, Albert; Dr. Ni Lin; and Dr. Li Leping).","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1198572504","isCrawlerRequest":true}